Most people have heard that fatty liver disease is common. Far fewer know that a specific form of it, now called metabolic dysfunction-associated steatotic liver disease, or MASLD, can quietly progress to cirrhosis, liver failure, or the need for a transplant. For decades, no drug had convincingly shown it could stop that progression in a large, rigorous trial.
A recruiting clinical trial called SYNERGY-OUTCOMES is trying to change that. The trial is testing two peptides, retatrutide and tirzepatide, against placebo in roughly 4,500 adults who have MASLD and whose non-invasive test results suggest they are at high risk for serious liver complications. According to the trial record posted on ClinicalTrials.gov, the study will run for approximately 224 weeks, which is just over four years, making it one of the longer and larger liver-disease trials on record.
This article explains what MASLD is, why researchers believe these particular peptides are worth studying, and what the trial is actually designed to measure.
What MASLD means and why it matters
MASLD is the updated medical term for what used to be called non-alcoholic fatty liver disease. The name change reflects a better scientific understanding: this condition is closely tied to metabolic factors such as excess body fat, insulin resistance, high blood sugar, and abnormal lipid levels rather than alcohol consumption.
In its early stages, MASLD involves fat accumulation in liver cells. For many people it stays mild. But in a meaningful subset, the liver becomes inflamed and scarred over time. Advanced scarring, called cirrhosis, can impair liver function severely and raise the risk of liver cancer and the need for transplant. Researchers use the term major adverse liver outcomes, or MALO, to describe this cluster of serious endpoints. The SYNERGY-OUTCOMES trial has been designed specifically to measure whether the two study peptides can reduce the rate of MALO.
The two peptides under investigation
Retatrutide is a triple-receptor agonist, meaning it activates three distinct hormonal receptors at once: the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. This triple action is thought to influence energy balance, glucose handling, and fat metabolism through overlapping but distinct pathways. Early-phase research has suggested that retatrutide produces substantial effects on body weight and metabolic markers, which is part of the rationale for studying it in a liver disease with strong metabolic roots.
Tirzepatide activates two of those same receptors, the GLP-1 and GIP receptors, making it a dual agonist. The literature on tirzepatide already includes data from large trials in type 2 diabetes and obesity, and researchers have noted improvements in liver enzyme levels and metabolic parameters in some of those populations. SYNERGY-OUTCOMES gives tirzepatide its first large-scale, prospective test specifically in high-risk MASLD with hard liver endpoints as the primary outcome.
Both peptides work by mimicking gut hormones that the body releases after eating. They influence insulin secretion, appetite signaling, and the way the body stores or burns fat. Because MASLD is fundamentally a metabolic disease, the hypothesis is that resetting these hormonal signals could slow or reverse the liver injury that accumulates over years.
Trial design and how participants are selected
SYNERGY-OUTCOMES uses what is called a master protocol structure. This means that multiple sub-studies, one for retatrutide and one for tirzepatide, operate under a single coordinating framework. Participants are randomly assigned to receive one of the two active peptides or a placebo. Using a shared placebo group and common outcome definitions allows the researchers to compare both agents against the same control standard while also gathering data that might eventually allow indirect comparisons between the two active arms.
The trial record specifies that participants are adults with MASLD diagnosed through non-invasive tests rather than liver biopsy. Non-invasive tests for liver fibrosis and steatosis, such as blood-based fibrosis scores, elastography, and imaging-based fat quantification, have become more reliable over the past decade. By using these tools as entry criteria, the trial avoids requiring an invasive biopsy for enrollment, which makes recruiting more feasible at scale.
Roughly 4,500 adults are planned for enrollment. Each participant will attend approximately 25 to 30 clinic visits over the course of the study to monitor liver function, disease progression, and overall health. The approximately 224-week duration reflects the reality that serious liver outcomes take years to develop, so meaningful data requires long-term follow-up.
The primary outcome researchers are watching
The central question of the trial is straightforward in concept: do fewer participants in the active treatment arms experience major adverse liver outcomes compared with those receiving placebo? MALO in this context refers to events such as progression to cirrhosis, liver decompensation, liver cancer, or death from liver-related causes.
This is a harder endpoint than some earlier liver disease trials that measured biopsy-based changes in inflammation or fibrosis score after one to two years. A long-term outcomes trial like SYNERGY-OUTCOMES is designed to show whether any biological changes these peptides produce actually translate into fewer patients progressing to the most serious stages of liver disease. Regulatory agencies and practicing physicians tend to place more confidence in outcomes-based trial data than in surrogate markers alone.
The extension phase and what it signals
After the main study concludes, eligible participants will have the option to join a two-year extension study. In the extension, all participants, including those who received placebo during the main trial, will be offered one of the two active peptides. This design serves a dual purpose. It provides additional long-term safety data for both compounds in an MASLD population, and it gives placebo participants eventual access to an active treatment after contributing several years to the research effort.
Extension studies in large metabolic trials have historically generated useful data about what happens when treatment begins later in the disease course, and whether benefits observed during the main trial are maintained or even enhanced with longer exposure. Those questions will likely take several more years to answer once the main trial concludes.
Context for the research peptide community
For those who follow research peptides and their mechanisms, the SYNERGY-OUTCOMES trial represents a significant moment in understanding how incretin-based compounds interact with the liver specifically. Most prior large trials for these peptide classes focused on glucose control or body weight as primary outcomes. Liver disease was typically a secondary or exploratory endpoint. This trial flips that priority, treating MALO as the central measure of success.
The inclusion of retatrutide is also notable because, at the time this trial began recruiting, the compound had fewer large-scale outcome data than tirzepatide. Running both agents in the same master protocol under identical conditions gives researchers an unusually clean look at how their profiles compare in this particular metabolic context.
Researchers and clinicians studying metabolic liver disease have pointed out that effective treatments for MASLD could reduce one of the fastest-growing causes of liver transplantation in many countries. The SYNERGY-OUTCOMES trial, by committing to a multi-year, outcomes-focused design with nearly five thousand participants, reflects the scientific community's recognition that this question deserves a serious, large-scale answer.
